Navigation Links
Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard

MENLO PARK, Calif., Sept. 19, 2013 /PRNewswire/ -- Protagonist Therapeutics today announced the addition of $4 million to its previously announced Series B private financing, bringing the total raised in this round to $18 million. Pharmstandard International S.A., a holding company of the major pharmaceutical company in Russia, OJSC Pharmstandard (LSE: PHST), has joined the round as a new investor.


"Protagonist's orally stable peptides represent a game-changing approach that especially enables the development of orally administered NCEs (new chemical entities) for inflammatory bowel diseases and other gastro-intestinal disorders," said Alexander Shuster, Ph.D., President of Inbio Ventures, a management company representing Pharmstandard International. "We were impressed by the company's technology, partnerships, development achievements to date, and the management team."

"The addition of Pharmstandard to our investor base reflects the growing international interest in the field of orally active peptides, as well as recognition by investors of the significant advantages offered by our technology over other approaches," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics. "This additional international investment enables us to further focus efforts on building a strong pipeline of developmental candidates for our internal pipeline and selective asset-based partnering."

About Pharmstandard International S.A./Inbio Ventures

Pharmstandard International S.A. – a holding company fully committed by OJSC Pharmstandard (LSE:PHST) – is a venture investments fund focused on innovative drugs/therapies with strong potential at global markets and in Russia and CIS countries. Inbio Ventures is a management company representing Pharmstandard International, S.A., and providing professional support in venture transactions.

About Protagonist Therapeutics

Protagonist Therapeutics is a U.S.-incorporated biotechnology company pursuing the discovery and development of 'orally stable peptides' against validated targets and diseases that are currently being addressed only by 'injectable biologics'.  Oral peptides can offer a superior choice to patients, physicians, and payers by virtue of their enhanced safety & efficacy, better convenience & compliance, and favorable affordability in comparison to the injectable antibodies. The company has a proprietary and validated technology platform comprised of well integrated computational, phage display and peptide chemistry discovery tools that are tailored to explore the full potential of oral peptide therapeutics.

Protagonist is a spin-out of University of Queensland's Institute of Molecular Biosciences (IMB) and is headquartered in the USA with discovery operations in Menlo Park, California USA and Brisbane, Queensland, Australia. For further information, please visit

SOURCE Protagonist Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
2. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
3. Adheron Therapeutics Names New Senior Leadership
4. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
5. Echo Therapeutics Sends Response to Shareholder Letter
6. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
7. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
8. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
9. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at
10. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
11. Oncology Therapeutics Market in India to 2018 Report
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... research firm Parks Associates announced today that Tom Kerber ... Annual Meeting , October 11 in Scottsdale, Arizona . ... how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer ... first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With ... with the challenge of how to continue to feed a growing nation. At the ...
Breaking Biology Technology:
(Date:8/23/2017)... Aug. 23, 2017  The general public,s help is being enlisted in ... that live in and on the human body –and are believed to ... The Microbiome Immunity Project ... microbiome, starting with the gut. The project's goal is to help advance ... IBM ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):